Condition
C-Peptide Effects on the QT/QTc Interval
Total Trials
1
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
5 treatments under study, led by Continental Breakfast
Related Conditions
Often studied with 4 related conditions
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 1 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
1Total
Phase 1 (1)
Trial Status
Completed1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Continental Breakfast1
- Moxifloxacin 400 Mg Fed1
- Moxifloxacin 400 Mg Fasted1
- Fda Breakfast1
- Insulin Clamp1
Active Sponsors
- Richmond Pharmacology Limited1
Top Investigators
Richmond Pharmacology Limited
Related Conditions
- Insulin And Oral Hypoglycemic Antidiabetic Drugs Causing Adverse Effects In Therapeutic Use1
- Moxifloxacin Ecg Profile In Fed And Fasted State1
- Japanese Vs Caucasian Tqt Comparison1
- Effects Of Different Meals On The Qtqtc Interval1